Michael Messig

2.7k total citations
43 papers, 2.0k citations indexed

About

Michael Messig is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Michael Messig has authored 43 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Surgery, 17 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Economics and Econometrics. Recurrent topics in Michael Messig's work include Lipoproteins and Cardiovascular Health (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Michael Messig is often cited by papers focused on Lipoproteins and Cardiovascular Health (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Michael Messig collaborates with scholars based in United States, France and Netherlands. Michael Messig's co-authors include Pierre Amarenco, Alfred Callahan, Larry B. Goldstein, Michael G. Hennerici, Henrik Sillesen, David D. Waters, Justin A. Zivin, K.M.A. Welch, Lisa Tarasenko and J. Wouter Jukema and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Michael Messig

43 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Messig United States	23	831	629	536	379	266	43	2.0k
Alain Nordmann Switzerland	24	763 0.9×	485 0.8×	580 1.1×	213 0.6×	220 0.8×	38	2.7k
Stella Trompet Netherlands	34	816 1.0×	741 1.2×	784 1.5×	179 0.5×	224 0.8×	149	3.7k
Graham Macdonald Australia	24	500 0.6×	672 1.1×	1.5k 2.8×	306 0.8×	164 0.6×	97	3.0k
Wilko Spiering Netherlands	32	525 0.6×	594 0.9×	1.5k 2.9×	320 0.8×	180 0.7×	170	3.3k
James L. Pool United States	36	857 1.0×	736 1.2×	1.1k 2.0×	482 1.3×	100 0.4×	118	3.4k
Mary Tan Canada	25	676 0.8×	282 0.4×	1.7k 3.1×	223 0.6×	235 0.9×	93	2.5k
Alan Rees United Kingdom	19	669 0.8×	410 0.7×	202 0.4×	66 0.2×	159 0.6×	36	1.7k
Davide Soranna Italy	28	427 0.5×	309 0.5×	713 1.3×	287 0.8×	218 0.8×	99	2.3k
Alex D. McMahon United Kingdom	20	812 1.0×	624 1.0×	423 0.8×	298 0.8×	71 0.3×	27	2.8k

Countries citing papers authored by Michael Messig

Since Specialization

Citations

This map shows the geographic impact of Michael Messig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Messig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Messig more than expected).

Fields of papers citing papers by Michael Messig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Messig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Messig. The network helps show where Michael Messig may publish in the future.

Co-authorship network of co-authors of Michael Messig

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Messig. A scholar is included among the top collaborators of Michael Messig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Messig. Michael Messig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shepherd, James, Andrei Breazna, Prakash Deedwania, et al.. (2016). Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology. 117(8). 1199–1205. 14 indexed citations

Kohli, Payal, David D. Waters, Rita Nemr, et al.. (2015). Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics. Journal of the American College of Cardiology. 65(4). 402–404. 35 indexed citations

Messig, Michael, Ching‐Ray Yu, Annlouise R. Assaf, et al.. (2015). The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women. Menopause The Journal of The North American Menopause Society. 23(4). 376–382. 9 indexed citations

Ninan, Philip T., et al.. (2015). Incidence and Timing of Taper/Posttherapy–Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder. The Primary Care Companion For CNS Disorders. 17(1). 6 indexed citations

Arnold, Lesley M., Pierre Arsenault, Cynthia Huffman, et al.. (2014). Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Current Medical Research and Opinion. 30(10). 2069–2083. 23 indexed citations

Abraham, Lucy, JoAnn V. Pinkerton, Michael Messig, et al.. (2014). Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 78(3). 212–218. 10 indexed citations

Ovbiagele, Bruce, Larry B. Goldstein, Pierre Amarenco, et al.. (2014). Prediction of Major Vascular Events after Stroke: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Journal of Stroke and Cerebrovascular Diseases. 23(4). 778–784. 6 indexed citations

Boudrez, Hedwig, et al.. (2013). PREDICTORS OF QUIT SUCCESS IN BELGIAN PARTICIPANTS OF A VARENICLINE OBSERVATIONAL SMOKING CESSATION STUDY. Acta Clinica Belgica. 68(1). 37–42. 2 indexed citations

Raskin, Philip, Cynthia Huffman, Cory Toth, et al.. (2013). Pregabalin in Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy. Clinical Journal of Pain. 30(5). 379–390. 30 indexed citations

10.

Rodríguez, Fátima, Raúl D. Santos, Michael Messig, et al.. (2012). Comparison of Lipid Profiles and Attainment of Lipid Goals in Patients <65 Years Versus Patients ≥65 Years (from the Lipid Treatment Assessment Project [L-TAP] 2). The American Journal of Cardiology. 109(12). 1738–1742. 6 indexed citations

11.

Chiang, Michael F., Raúl D. Santos, David D. Waters, et al.. (2011). Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2). The American Journal of Cardiology. 107(11). 1639–1643. 7 indexed citations

12.

Bittner, Vera, Nanette K. Wenger, David D. Waters, et al.. (2010). VITAMIN D LEVELS ARE NOT RELATED TO MYALGIAS IN STATIN-TREATED PATIENTS WITH STABLE CORONARY DISEASE. Journal of the American College of Cardiology. 55(10). A177.E1659–A177.E1659. 8 indexed citations

13.

Bittner, Vera, Nanette K. Wenger, David D. Waters, et al.. (2010). VITAMIN D LEVELS DO NOT PREDICT CARDIOVASCULAR EVENTS IN STATIN-TREATED PATIENTS WITH STABLE CORONARY DISEASE. Journal of the American College of Cardiology. 55(10). A167.E1570–A167.E1570. 4 indexed citations

14.

Fagerström, K., Hans Gilljam, Michael Metcalfe, Serena Tonstad, & Michael Messig. (2010). Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 341(dec06 1). c6549–c6549. 57 indexed citations

15.

Gandelman, Kuan, Gordon Fung, Michael Messig, & Rachel Laskey. (2010). Systemic Exposure to Atorvastatin Between Asian and Caucasian Subjects. American Journal of Therapeutics. 19(3). 164–173. 27 indexed citations

16.

Santos, Raúl D., David D. Waters, Lisa Tarasenko, et al.. (2009). Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. American Heart Journal. 158(5). 860–866. 38 indexed citations

17.

Sillesen, Henrik, Pierre Amarenco, Michael G. Hennerici, et al.. (2008). Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis. Stroke. 39(12). 3297–3302. 173 indexed citations

18.

Jiménez, Camilo, Pia Burman, Roger Abs, et al.. (2008). Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology. 159(5). 517–523. 46 indexed citations

19.

Campese, Vito M., Alfred Callahan, Amy E. Rudolph, et al.. (2007). Abstract 2173: Effect of High-dose Atorvastatin on Changes in Renal Function: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) Trial. Circulation. 116. 1 indexed citations

20.

Wagner, Karen Dineen, Edwin H. Cook, Henry Chung, & Michael Messig. (2003). Remission Status After Long-Term Sertraline Treatment of Pediatric Obsessive-Compulsive Disorder. Journal of Child and Adolescent Psychopharmacology. 13(supplement 1). 53–60. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact